New educational resources will make it
easier for people at high risk of progression to severe COVID-19 to
protect their health through accessible and timely health
information
Cue Health (“Cue”) (Nasdaq: HLTH), the healthcare technology
leader in at-home and point-of-care diagnostic innovations, today
announced a new collaboration with Pfizer Inc. in the U.S. to raise
awareness among individuals with certain underlying conditions
about the risks of progressing to severe COVID-19 and the
importance of seeking treatment if they test positive. Through Cue
Care, Cue’s same-day, at-home, test-to-treatment platform,
individuals will be able to use the Cue Health App to access
educational resources like those available on Pfizer’s
www.knowplango.com website, including information on risk factors
for progression to severe illness from COVID-19, including
hospitalization or death.
“The recent guidance from the CDC underscores the continued
importance of testing even when symptoms are mild, timely access to
healthcare providers, and, where appropriate, treatment for those
most vulnerable to the COVID-19 variants in circulation,” said
David Tsay, MD, PhD, chief medical officer at Cue Health. “Cue’s
platform offers people support for each of those critical needs and
is now integrating educational resources into Cue Care as part of
this collaboration with Pfizer. Together, this actionable health
information will help individuals make more informed decisions that
can lead to better health outcomes.”
This COVID-19 collaboration with Pfizer builds on recent
initiatives launched by Cue to rapidly connect at-risk individuals
with providers for care and, where appropriate, treatment.
“Connected health solutions like the Cue platform offer
potential for faster and more convenient access to care. Our
collaboration provides an opportunity to improve the
test-to-treatment experience for patients and communities at high
risk, which includes people 50 years of age and older,” said JoyL
Silva, Global and U.S. Antiviral Franchise Lead, Pfizer.
While these educational resources are specific to COVID-19
today, the Cue platform is designed to support a wide range of
diagnostic test-to-treatment areas, and the company plans to make
educational resources about treatment and recovery available for
other respiratory viruses and sexual health conditions in the
future.
Last month, Cue announced a partnership with Scripps Research
Translational Institute to launch ImmunoCARE, a remote trial
utilizing Cue’s test-to-treatment platform, aimed at reducing
hospitalizations and other severe outcomes in immunocompromised
people infected with SARS-CoV-2, the virus that causes COVID-19.
Further, in December, Cue announced it was selected by the
Minnesota Department of Health (MDH) to provide a statewide
COVID-19 telehealth to treatment program at no cost to Minnesota
residents, powered by Cue Care.
Cue’s COVID-19 test was the first molecular diagnostic test
available to consumers without a prescription and is the most
accurate at-home COVID-19 test*, delivering results in 20 minutes
to connected mobile devices. It detects all known COVID-19 variants
of concern in people with or without symptoms. Cue is used in
homes, in point-of-care settings, and by world-class organizations
across the country, including Mayo Clinic, Johns Hopkins Medicine,
Google, and the National Basketball Association, among many
others.
An independent study by Mayo Clinic, released in 2021, found
Cue's COVID-19 test showed 97.8% concordance with central lab PCR
tests.
*Accuracy claim based on comparison of clinical study results
submitted to the U.S. Food and Drug Administration (FDA) for
Emergency Use Authorization for Cue and other molecular home
tests.
About Cue Health
Cue Health (Nasdaq: HLTH) is a healthcare technology company
that makes it easier for individuals to access health information
and places diagnostic information at the center of care. Cue Health
enables people to manage their health through real-time,
actionable, and connected health information, offering individuals
and their healthcare providers easy access to lab-quality
diagnostics anywhere, anytime, in a device that fits in the palm of
the hand. Cue Health's first-of-its-kind COVID-19 test was the
first FDA-authorized molecular diagnostic test for at-home and
over-the-counter use without a prescription and physician
supervision. Outside the United States, Cue Health has received the
CE mark in the European Union, Interim Order authorization from
Health Canada, regulatory approval from India's Central Drugs
Standard Control Organization, and PSAR authorization from
Singapore’s Health Sciences Authority. Cue was founded in 2010 and
is headquartered in San Diego. For more information, please visit
www.cuehealth.com.
Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
“forward-looking statements”. The words, without limitation,
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these or similar identifying
words. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including those related to the expected future diagnostic
test menu and the factors discussed in the “Risk Factors” section
of Cue’s Annual Report on Form 10-K for the year ended December 31,
2021 and Quarterly Report on Form 10-Q for the quarter ended
September 30, 2022 filed with the SEC on November 9, 2022. Any
forward-looking statements contained in this press release are
based on the current expectations of Cue’s management team and
speak only as of the date hereof, and Cue specifically disclaims
any obligation to update any forward-looking statement, whether as
a result of new information, future events or otherwise.
Cue’s COVID-19 tests have not been FDA cleared or approved; but
have been authorized by FDA and under an Emergency Use
Authorization (EUA). These products have been authorized only for
the detection of nucleic acid from SARS-CoV-2, not for any other
viruses or pathogens. The emergency use of these products is only
authorized for the duration of the declaration that circumstances
exist justifying the authorization of emergency use of in vitro
diagnostics for detection and/or diagnosis of COVID-19 under
Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21
U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or
authorization is revoked sooner.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230302005305/en/
MEDIA INQUIRIES press@cuehealth.com
Cue Health (NASDAQ:HLTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cue Health (NASDAQ:HLTH)
Historical Stock Chart
From Jul 2023 to Jul 2024